U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C5H5O5.Na
Molecular Weight 168.08
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MONOSODIUM OXOGLURATE

SMILES

[Na+].OC(=O)CCC(=O)C([O-])=O

InChI

InChIKey=MOTOGHHLNTXPTI-UHFFFAOYSA-M
InChI=1S/C5H6O5.Na/c6-3(5(9)10)1-2-4(7)8;/h1-2H2,(H,7,8)(H,9,10);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula C5H5O5
Molecular Weight 145.0902
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.uofmhealth.org/health-library/hn-4451004 | https://www.ncbi.nlm.nih.gov/pubmed/27326424 | https://www.ncbi.nlm.nih.gov/pubmed/26122777 | https://www.ncbi.nlm.nih.gov/pubmed/26759695 | https://www.ncbi.nlm.nih.gov/pubmed/10453328

Alpha-ketoglutarate (AKG), an endogenous intermediary metabolite in the Krebs cycle, is a molecule involved in multiple metabolic and cellular pathways. As an intermediate of the tricarboxylic acid cycle, AKG is essential for the oxidation of fatty acids, amino acids, and glucose. Extracellular AKG is a significant source of energy for cells of the gastrointestinal tract. As a precursor for the synthesis of glutamate and glutamine in multiple tissues (including liver, skeletal muscle, heart, brain, and white adipose tissue), AKG bridges carbohydrate and nitrogen metabolism for both conservation of amino acids and ammonia detoxification. Additionally, emerging evidence shows that AKG is a regulator of gene expression and cell signaling pathways (including the mammalian target of rapamycin and AMPactivated protein kinase). Thus, AKG is an attractive dietary supplement in animal and human nutrition to improve cellular energy status, immunity, and health.AKG can decrease protein catabolism and increase protein synthesis to enhance bone tissue formation in the skeletal muscles and can be used in clinical applications. In addition to these health benefits, a recent study has shown that AKG can extend the lifespan of adult Caenorhabditis elegans by inhibiting ATP synthase and TOR. Orally, AKG is used for kidney disease, gastrointestinal disorders, bacterial overgrowth, intestinal toxemia, liver dysfunction, and chronic candidiasis. It is also used for improving peak athletic performance, improving amino acid metabolism in hemodialysis patients, and cataracts. Intravenously, AKG is used for preventing ischemic injury during heart surgery, improving renal blood flow after heart surgery, and preventing muscle protein depletion after surgery or trauma.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Primary
ORNITHINE ALPHA-KETOGLUTARATE

Approved Use

Ornithine alpha-ketoglutarate (OKG) administration improves nutritional status in chronically malnourished (e.g., elderly) and acutely malnourished patients (especially burn and trauma patients).
Primary
ALPHA-KETOGLUTARATE

Approved Use

Orally, alpha-ketoglutarate is used for kidney disease, gastrointestinal disorders, bacterial overgrowth, intestinal toxemia, liver dysfunction, and chronic candidiasis. It is also used for improving peak athletic performance, improving amino acid metabolism in hemodialysis patients, and cataracts. Intravenously, alpha-ketoglutarate is used for preventing ischemic injury during heart surgery, improving renal blood flow after heart surgery, and preventing muscle protein depletion after surgery or trauma.
PubMed

PubMed

TitleDatePubMed
[1 (+) ornithine alpha ketoglutarate in hepatic encephalopathy].
1970 Jun 20
Effect of ornithine alpha ketoglutarate (OAKG) on the response of brain metabolism to hypoxia in the dog.
1978 May-Jun
[A controlled trial of ornithine alpha-ketoglutarate in neuro-traumatology].
1986 Oct
The use of alpha-ketoglutarate salts in clinical nutrition and metabolic care.
1999 Jan
Nutritional and clinical efficacy of ornithine alpha-ketoglutarate in severe burn patients.
1999 Oct
Effect of alpha-ketoglutarate and oxaloacetate on brain mitochondrial DNA damage and seizures induced by kainic acid in mice.
2003 Jul 20
Ornithine alpha-ketoglutarate as a potent precursor of arginine and nitric oxide: a new job for an old friend.
2004 Oct
In vitro and in vivo evaluation of various carbonyl compounds against cyanide toxicity with particular reference to alpha-ketoglutaric acid.
2008
The absorption, tissue distribution and excretion of enteraly administered alpha-ketoglutarate in rats.
2008 Apr
Artefacts in cell culture: α-Ketoglutarate can scavenge hydrogen peroxide generated by ascorbate and epigallocatechin gallate in cell culture media.
2011 Mar 4
The metabolite α-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR.
2014 Jun 19
The Physiological Basis and Nutritional Function of Alpha-ketoglutarate.
2015
The biological role of a-ketoglutaric acid in physiological processes and its therapeutic potential.
2016 Jan-Mar
Alpha-Ketoglutarate as a Molecule with Pleiotropic Activity: Well-Known and Novel Possibilities of Therapeutic Use.
2017 Feb
Patents

Sample Use Guides

1 capsule daily
Route of Administration: Oral
It was investigated the efficacy of several carbonyl compounds and their metabolites or nutrients with alpha-ketoglutaric acid (A-KG), citric acid, succinic acid, maleic acid, malic acid, fumaric and oxaloacetic acid, glucose, sucrose, fructose, mannitol, sorbitol, dihydroxyacetone, and glyoxal (5 or 10 mM; -10 min) against toxicity of potassium cyanide (KCN; 10 mM) in rat thymocytes in vitro. Six hours after KCN, cell viability measured by MTT assay and crystal violet dye exclusion revealed maximum cytoprotection by A-KG, followed by oxaloacetic acid. A-KG also resolved the leakage of intracellular lactate dehydrogenase, loss in nuclear integrity (propidium iodide staining), and altered mitochondrial membrane potential (rhodamine 123 assay) as a result of cyanide toxicity. Protection Index (ratio of LD(50) of KCN in protected and unprotected animals; PI) of all the compounds (oral; 1.0 g/kg; -10 min) determined in male mice, revealed that maximum protection was afforded by A-KG (7.6 PI), followed by oxaloacetic acid (6.4 PI). Comparative evaluation of various salts of A-KG alone or with STS (intraperitoneal; 1.0 g/kg; -15 min) showed that maximum protection was conferred by disodium anhydrous salt of A-KG, which also significantly prevented the inhibition of brain cytochrome oxidase caused by 0.75 LD(50) KCN.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:06:28 UTC 2023
Edited
by admin
on Fri Dec 15 15:06:28 UTC 2023
Record UNII
8GFV60F71R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MONOSODIUM OXOGLURATE
Common Name English
MONOSODIUM 2-OXOGLUTARATE
Systematic Name English
PENTANEDIOIC ACID, 2-OXO-, MONOSODIUM SALT
Systematic Name English
SODIUM HYDROGEN .ALPHA.-KETOGLUTARATE
Common Name English
GLUTARIC ACID, 2-OXO-, MONOSODIUM SALT
Systematic Name English
ALPHA-KETO-GLUTARIC ACID, SODIUM SALT
Common Name English
MONOSODIUM .ALPHA.-KETOGLUTARATE
Common Name English
PENTANEDIOIC ACID, 2-OXO-, SODIUM SALT (1:1)
Systematic Name English
.ALPHA.-KETOGLUTARIC ACID MONOSODIUM SALT
Common Name English
Code System Code Type Description
FDA UNII
8GFV60F71R
Created by admin on Fri Dec 15 15:06:28 UTC 2023 , Edited by admin on Fri Dec 15 15:06:28 UTC 2023
PRIMARY
PUBCHEM
23670750
Created by admin on Fri Dec 15 15:06:28 UTC 2023 , Edited by admin on Fri Dec 15 15:06:28 UTC 2023
PRIMARY
ECHA (EC/EINECS)
244-836-6
Created by admin on Fri Dec 15 15:06:28 UTC 2023 , Edited by admin on Fri Dec 15 15:06:28 UTC 2023
PRIMARY
CAS
17091-15-5
Created by admin on Fri Dec 15 15:06:28 UTC 2023 , Edited by admin on Fri Dec 15 15:06:28 UTC 2023
NON-SPECIFIC STOICHIOMETRY
EPA CompTox
DTXSID70944861
Created by admin on Fri Dec 15 15:06:28 UTC 2023 , Edited by admin on Fri Dec 15 15:06:28 UTC 2023
PRIMARY
CAS
22202-68-2
Created by admin on Fri Dec 15 15:06:28 UTC 2023 , Edited by admin on Fri Dec 15 15:06:28 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE